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Abstract
Background: The spectrum of bacteria associated with bacterial vaginosis (BV) has recently expanded through taxonomic
changes and the use of molecular methods. These methods have yet to be used in large-scale epidemiological studies in
Africa where BV is highly prevalent.
Methods: An analysis of samples obtained during a clinical trial of the management of vaginal discharge in four West
African countries. Samples were available from 1555 participants; 843 (54%) had BV. Nucleic acids of 13 bacterial genera or
species potentially associated with BV were detected through the polymerase chain reaction.
Results: The associations between various components of the vaginal flora were complex. Excluding Lactobacillus, the other
12 micro-organisms were all associated with each other at the p#0.001 level. The prevalence of various bacterial genera or
species varied according to age, sexual activity and HIV status. In multivariate analysis, the presence of Gardnerella vaginalis,
Bifidobacterium, Megasphaera elsdenii, Dialister, Mycoplasma hominis, Leptotrichia, and Prevotella were independently
associated with BV as was the absence of Lactobacillus and Peptoniphilus. However, Mobiluncus, Atopobium vaginae,
Anaerococcus, and Eggerthella were not independently associated with BV. Unexpectedly, after treatment with a regimen
that included either metronidazole or tinidazole, the proportion of patients with a complete resolution of symptoms by day
14 increased with the number of bacterial genera or species present at enrolment.
Conclusions: Numerous bacterial genera or species were strongly associated with each other in a pattern that suggested a
symbiotic relationship. BV cases with a simpler flora were less likely to respond to treatment. Overall, the vaginal flora of
West African women with BV was reminiscent of that of their counterparts in industrialized countries.
Citation: Pe ´pin J, Deslandes S, Giroux G, Sobe ´la F, Khonde N, et al. (2011) The Complex Vaginal Flora of West African Women with Bacterial Vaginosis. PLoS
ONE 6(9): e25082. doi:10.1371/journal.pone.0025082
Editor: Rupert Kaul, University of Toronto, Canada
Received May 19, 2011; Accepted August 25, 2011; Published September 20, 2011
Copyright:  2011 Pepin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by the Canadian International Development Agency through its West Africa Project to Combat AIDS and STI in West Africa. The
funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jacques.pepin@usherbrooke.ca
Introduction
Bacterial vaginosis (BV) is the most common cause of vaginal
discharge, both in industrialized and developing countries and
among the HIV-infected and uninfected [1,2]. Its main detrimental
effect on pregnancy is preterm delivery [3]. Cross-sectional and
cohort studies have revealed a bidirectional association between BV
and HIV infection [4–7]. Meta-analyses estimated that BV
increases the risk of male-to-female transmission of HIV by 40–
60% [8]. To date, there is no evidence that treatment of BV reduces
the risk of HIV, but the high prevalence of BV suggests that its
population-attributable fraction of incident HIV among women
could be substantial. By increasing genital shedding of HIV, BV
might also impact on female-to-male HIV transmission [9].
BV is attributed to a disturbance in the vaginal flora, with fewer
lactobacilli and increasing numbers of anaerobic Gram-negative
rods. Its etiological agents remain debated, as BV appears to be a
polymicrobial process with interrelated organisms leading to a
common outcome. Gardnerella vaginalis is only one among several
bacterial genera or species that are more common or present in
larger quantities in women with BV compared to healthy controls;
others include Mycoplasma hominis, Mobiluncus spp., Prevotella spp.,
Atopobium vaginae, Eggerthella spp., Megasphaera spp., Leptotrichia spp.,
Peptoniphilus spp., Anaerococcus spp., Dialister spp. and novel bacteria
in the order Clostridiales [10–17].
Studies on the microbial correlates of BV have been undertaken in
industrialized countries, but less is known about the association
between these bacteria and BV in Sub-Saharan Africa, where BV is
extremely common and could impact on HIV transmission [18–20].
Furthermore, no study using nucleic acid amplification measured the
association between multiple genera or species and BV in a
population large enough for the confounding effects of multiple
organisms to be taken into consideration. To better understand the
microbiologyofBVinAfricaandultimatelytodevelopmoreeffective
treatments, we looked for putative pathogens among participants in a
study of the vaginal discharge syndrome in West Africa.
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This study is a sub-analysis of data collected during a
randomized controlled trial for the management of symptomatic
vaginal discharge. Subjects presenting with symptoms of vaginal
discharge were randomized to metronidazole 500 mg twice a day
for seven days plus clotrimazole cream for three days versus single-
dose treatment with tinidazole (2 g) plus fluconazole (150 mg)
(ClinicalTrials.gov NCT00313131) [2].
Ethics statement
The protocol was approved by the Ethical Review Committee
of the Ghana Health Service, the Comite ´ National d’E ´thique pour la
Recherche en Sante ´ (Guine ´e), the Comite ´ d’E ´thique de l’Institut National de
Recherche en Sante ´ Publique du Mali, the Comite ´ d’E ´thique sur la Recherche
en Sante ´ (Togo), and the Comite ´ d’E ´thique de la Recherche sur l’Humain
du Centre Hospitalier Universitaire de Sherbrooke et de la Faculte ´d eM e ´decine
de l’Universite ´ de Sherbrooke (Canada).
Data collection
Between January 2004 and April 2005, women complaining of
vaginal discharge were recruited in nine healthcare facilities in
four West African countries: i) in Ghana, the sexually transmitted
infections (STI) clinics of Accra-Adabraka and Kumasi-Suntreso;
ii) in Togo, the STI clinics of Amoutive ´, Agoe ´-Nyive ´ and
Adakpame ´; iii) in Conakry, Guinea, the Madina, and Carrie `re
health centers; iv) in Bamako, Mali, the Korofina, and Soutoura
health centers. Pregnant women, those who complained of
abdominal pain, those who were not local residents, and those
with allergies to one or more study drugs were excluded. After
giving written informed consent, participants were identified only
by number. Laboratory assays were performed anonymously
through an unlinked method. Participants wishing to know their
HIV status received pre-test counseling and a duly identified
sample was obtained. Processing of this sample, post-test
counseling and referral to a treatment facility were performed
per clinic routine.
At the initial visit, a questionnaire gathered demographic,
behavioral, and clinical information. Samples were obtained from
vaginal and cervical secretions. First, a vaginal fluid sample was
deposited in a transport medium and used for the detection of
pathogens by the polymerase chain reaction (PCR). A second
vaginal sample was used to deposit secretions on a slide that was
Gram stained to detect the presence of BV, defined as a Nugent
score $7 [21]. Yeast, with phenotype compatible with Candida
albicans, was noted when present. A cervical sample was tested by
PCR for the presence of Neisseria gonorrhoeae, Chlamydia trachomatis,
and Mycoplasma genitalium. HIV serology was performed on
capillary blood [2]. All enrolled participants were randomized to
one of the treatment regimens and were asked to return 14 days
later to document their symptomatic response.
Detection of vaginal pathogens
Methods for PCR assays are described in Text S1 and Table S1
[14,22–27]. Initially, we sought to detect nucleic acids of
Trichomonas vaginalis, G. vaginalis, A. vaginae, Prevotella spp., Mobiluncus
spp., M. hominis and Lactobacillus spp in all vaginal samples obtained
upon enrolment. During the course of the study, as the number of
putative pathogens reported by other researchers increased, a
preliminary screening of additional bacterial genera or species was
performed on randomly selected samples with (n=100) and
without BV (n=100). Testing of all samples was performed only
for pathogens that showed an association with BV at the p,0.05
level on this subset, including Leptotrichia spp., Eggerthella spp.,
Megasphaera elsdenii, Dialister spp., Bifidobacterium spp., Peptoniphilus
spp. with primers that excluded P. lacrimalis, and Anaerococcus spp.
BVAB-1, BVAB-2, BVAB-3, Peptoniphilus lacrimalis, and the
Clostridium coccoides group were not associated with BV at the
p,0.05 level, and therefore, all samples were not tested for these
species.
Data analysis
Data were analyzed with Stata 10.0 (StataCorp LP, College
Station, Texas). Proportions were compared with the x
2 test. In
preliminary analyses, we first examined the associations between
various bacterial genera or species. We also evaluated the
distribution of bacterial species or genera according to age, HIV
status, and number of sexual partners. In the main analysis, we
examined the association between various bacterial genera or
species and the outcome, which was BV defined as per a Nugent
score $7. Logistic regression was used for multivariate analysis.
Models were built sequentially starting with the variable most
strongly associated with the outcome and continuing until no other
variable reached significance or altered the odds ratios of variables
already in the model. When the final model was reached, each
variable was dropped in turn to assess its effect using the likelihood
ratio test. Results are presented as adjusted odds ratios (AOR) with
their 95% confidence intervals (CI).
Results
Samples were available from 1555 participants, of whom 843
(54%) had BV. As reported elsewhere, 30% had candidiasis, 10%
had trichomoniasis, and cervical pathogens (N. gonorrhoeae, C.
trachomatis,o rM. genitalium) were found in 11%, while 32% of cases
had no clear etiology of the vaginal discharge elicited [2]. Table 1
shows the associations between microorganisms among all
participants as correlation coefficients, while Table S2 displays
the distribution of bacterial species or genera. Lactobacillus was the
most frequently detected, followed by Bifidobacterium. Conversely,
Mobiluncus was rarely detected. Excluding Lactobacillus, the other 12
micro-organisms were all associated with each other at the
p#0.001 level. In contrast, Lactobacillus poorly correlated with
the presence or absence of other microorganisms, and those
associations that were significant because of the large sample size
were not impressive for their absolute differences in prevalence.
We examined the distribution of various bacterial genera or
species among all participants. To simplify the presentation and
comparisons between microorganisms, Table 2 displays the results
of a common multivariate model, using each micro-organism as
the outcome sequentially. More detailed data are available in
Tables S3, S4, S5, and S6. In the West African societies where this
recruitment occurred, most women (440/472 [93%]) who
reported having had more than one sexual partner over the
preceding three months were sex workers with numerous partners.
Older age was associated with lower likelihood of colonization/
infection with G. vaginalis, M. hominis, A. vaginae, Eggerthella,
Leptotrichia, Dialister, and Bifidobacterium. Being sexually active was
associated with colonization/infection with G. vaginalis, Prevotella,
Mobiluncus, Eggerthella, Leptotrichia, and Bifidobacterium and was
inversely associated with Lactobacillus colonization. For some
pathogens, there was little difference related to the degree of
sexual activity (comparing $2 partners to 1 partner), while others
(Prevotella, Eggerthella, Leptotrichia and Bifidobacterium) were more
prevalent among women with $2 partners. HIV infection was
associated with colonization/infection with G. vaginalis, M. hominis,
Prevotella, Mobiluncus, Eggerthella, Leptotrichia, Dialister, Bifidobacterium,
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being colonized with Lactobacillus.
Table 3 shows the correlates of BV in univariate analyses. BV
was more frequent in younger women, sexually active women, and
HIV-infected women. BV prevalence was equal among sex
workers and non-sex workers. BV was strongly associated with
G. vaginalis, M. hominis, A. vaginae, Prevotella, Mobiluncus, Leptotrichia,
M. elsdenii, Eggerthella, Dialister, Bifidobacterium, and Anaerococcus
(crude odds ratios $3.0) and less strongly associated with
Peptoniphilus non-lacrimalis and pathogens not thought to be causal
agents of BV (T. vaginalis, C. trachomatis,o rM. genitalium) (crude
odds ratios #2.0). Presence of Lactobacillus was associated with
lower odds of BV. Yeast infections were equally frequent in
women with or without BV.
Table 4 shows the results of the multivariate analysis of
correlates of BV. Number of sexual partners increased the fit of the
model even if each category was not significant. Age and HIV
status became non-significant and were left out. The presence of G.
vaginalis, Bifidobacterium, M. elsdenii, Dialister, M. hominis, Leptotrichia,
and Prevotella was independently associated with BV as was the
absence of Lactobacillus and Peptoniphilus non-lacrimalis. When fitted
into this model, the following pathogens were no longer
independently associated with BV: A. vaginae (AOR: 1.30; 95%
CI: 0.95–1.78; p=0.10), Mobiluncus (AOR: 1.36; 95% CI: 0.72–
2.56; p=0.34), Anaerococcus (AOR: 1.17; 95% CI: 0.83–1.66;
p=0.37) and Eggerthella (AOR: 1.03; 95% CI: 0.71–1.50; p=0.86).
The presence of T. vaginalis, N. gonorrhoeae, C. trachomatis,o rM.
genitalium was not independently associated with BV after
adjustment for the other correlates of BV (data not shown).
The robustness of our conclusions was tested on alternative
models. As it could be argued that the presence of Lactobacillus by
PCR was too directly related to the Gram stain definition of BV,
this variable was excluded in a subsequent model, which showed
that the same eight micro-organisms were associated with BV,
while the same four were not significantly associated (data not
shown). In models (with or without Lactobacillus) that excluded
women with an intermediate Nugent score (4–6), G. vaginalis,
Bifidobacterium, Dialister, M. hominis, Leptotrichia, and Prevotella
remained associated with BV, while the presence of M. elsdenii
and the absence of Peptoniphilus non-lacrimalis became non-
significant (Tables S7 and S8). Likewise, A. vaginae, Mobiluncus,
Eggerthella, and Anaerococcus were not significantly associated with
BV.
Of 349 women without evidence of G. vaginalis, M. hominis,
Prevotella, Leptotrichia, M. elsdenii, Dialister, and Bifidobacterium, only
12% (41) had BV as diagnosed by Nugent score. This proportion
increased to 25% (54/220), 44% (104/236), 53% (101/189), 68%
(126/184), 70% (120/171), 84% (133/158) and 89% (33/37) for
women with respectively one, two, three, four, five, six or all of
these microorganisms respectively (p,0.001, x
2 for trend).
In a secondary analysis that included all 570 women with BV
who attended their follow-up visit on day 14 (Table S9), the
proportion with a complete resolution of symptoms increased with
the number of pathogens identified on day 0: 41% of those with a
single pathogen, and 57%, 56%, 58%, 70%, 64%, 70%, and 76%
of those with one, two, three, four, five, six, or seven pathogens
respectively (p,0.001, x
2 for trend) had complete resolution of
symptoms. This trend was stronger in participants who had been
treated with single-dose tinidazole/fluconazole than for those
treated with metronidazole/clotrimazole. Age and HIV status had
no impact on the likelihood of a complete short-term response to
treatment. In a multivariate analysis, complete resolution of
symptoms on day 14 was more common in women in whose
samples Prevotella (AOR: 1.91; 95% CI: 1.34–2.74; p,0.001) or M.
elsdenii (AOR: 1.54; 95% CI: 1.01–2.34; p=0.04) had been
detected and among those with $2 sex partners (AOR: 1.95; 95%
CI: 0.97–3.93; p=0.06). No other pathogens or the treatment
allocation was independently associated with this complete short-
term resolution of symptoms.
Discussion
We documented complex interrelationships between several
micro-organisms present in the vaginal flora of a large number of
women presenting with vaginal discharge in West Africa. These
organisms were strongly associated with each other to an extent
that can hardly be explained by shared risk factors for transmission
Table 1. Associations between various bacterial species and genera.
1
GV MH AV MO PR AN BI DI LE ME PE LA
GV 1 0.320 0.580 0.085 0.394 0.288 0.517 0.304 0.367 0.181 0.206 0.112
MH 1 0.365 0.168 0.331 0.228 0.256 0.339 0.421 0.159 0.195 0.020
AV 1 0.139 0.384 0.417 0.395 0.375 0.388 0.250 0.250 0.084
MO 1 0.207 0.135 0.091 0.221 0.215 0.106 0.107 20.136
PR 1 0.286 0.378 0.401 0.464 0.181 0.275 20.042
AN 1 0.327 0.432 0.343 0.222 0.306 20.054
BI 1 0.397 0.400 0.216 0.236 20.097
DI 1 0.510 0.261 0.400 20.046
LE 1 0.391 0.245 20.093
ME 1 0.086 20.079
PE 1 0.083
LA 1
1Correlation coefficients (phi) were used to measure associations between dichotomic variables and are displayed in the table. All correlations had p-values ,0.001,
excepted LA-ME (0.002), LA-AN (0.03), LA-DI (0.07), LA-PR (0.10), and LA-MH (0.43).
Note: GV: Gardnerella vaginalis; AV: Atopobium vaginae; MH: Mycoplasma hominis;
PR: Prevotella; MO: Mobiluncus; LE: Leptotrichia;M E :Megasphaera elsdenii;
EG: Eggerthella;D I :Dialister (DI); BI Bifidobacterium (BI); AN: Anaerococcus;P EPeptoniphilus other than lacrimalis;L A :Lactobacillus (LA).
doi:10.1371/journal.pone.0025082.t001
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ecosystem [10,11]. Many organisms were associated with BV in
univariate analyses but four became non-significant after adjust-
ment for the presence of other bacteria. Previous analyses of the
microbiology of BV considered only some of these organisms, used
only univariate analyses, or combined all pathogens into a
composite variable [11–15,17]. Our sample size was substantially
larger than all previous studies and allowed us to adjust for the
concomitant presence of multiple bacteria. Amongst our partic-
ipants, Mobiluncus, Eggerthella, Anaerococcus, and A. vaginae were not
independently associated with BV but were rather confounded by
their association with other genera or species that themselves were
correlates of BV. Our results support the idea that G. vaginalis,
Bifidobacterium, M. elsdenii, Dialister, M. hominis, Leptotrichia, and
Prevotella are associated with BV and that its microbiology is the
same in Africa as in industrialized countries.
Our interpretation of Table 2 is as follows. Colonization/
infection with several organisms was enhanced by sexual activity
and by HIV-associated immunosuppression. Some organisms
must be transmitted during intercourse. For others, organisms that
are equally prevalent in sex workers and monogamous sexually
active women, a non-specific effect of intercourse on the vaginal
Table 2. Correlates of colonization/infection with various bacterial genera or species.
G. vaginalis M. hominis A. vaginae Prevotella Mobiluncus
Age, years
#20 1.00 1.00 1.00 1.00 1.00
21–30 0.82 (0.64–1.06) 0.67 (0.50–0.90)
2 0.77 (0.60–0.99)
2 0.98 (0.76–1.27) 1.52 (0.83–2.77)
$31 0.59 (0.44–0.81)
1 0.46 (0.32–0.67)
1 0.73 (0.54–0.99)
2 0.91 (0.67–1.24) 1.14 (0.56–2.35)
Sex partners, last 3 months
None 1.00 1.00 1.00 1.00 1.00
One 1.37 (0.98–1.91) 1.27 (0.84–1.92) 1.20 (0.86–1.70) 1.04 (0.74–1.46) 3.02(1.08–8.47)
2
Two or more 1.45 (1.01–2.07)
2 1.14 (0.73–1.76) 1.16 (0.81–1.67) 1.58 (1.10–2.26)
2 1.73 (0.58–5.15)
HIV
Negative 1.00 1.00 1.00 1.00 1.00
Positive 1.77 (1.29–2.42)
1 2.06 (1.47–2.87)
1 1.12 (0.82–1.52) 1.86 (1.37–2.54)
1 2.19(1.27–3.80)
2
Eggerthella M. elsdenii Leptotrichia Dialister Bifidobacterium
Age, years
#20 1.00 1.00 1.00 1.00 1.00
21–30 0.73 (0.56–0.95)
2 0.94 (0.66–1.33) 0.71 (0.55–0.92)
2 0.78 (0.59–1.04) 0.74(0.56–0.96)
2
$31 0.48 (0.34–0.68)
1 0.81 (0.52–1.25) 0.53 (0.38–0.73)
1 0.60 (0.42–0.86)
2 0.50(0.36–0.68)
1
Sex partners, last 3 months
None 1.00 1.00 1.00 1.00 1.00
One 1.29 (0.87–1.91) 1.32 (0.80–2.17) 1.26 (0.88–1.81) 1.10 (0.74–1.64) 1.29 (0.92–1.81)
Two or more 1.59 (1.05–2.40)
2 1.21 (0.71–2.06) 1.81 (1.24–2.66)
2 1.26 (0.83–1.91) 1.61 (1.11–2.32)
2
HIV
Negative 1.00 1.00 1.00 1.00 1.00
Positive 1.41 (1.02–1.96)
2 1.03 (0.67–1.57) 1.59 (1.17–2.17)
2 1.73 (1.25–2.40)
1 2.07(1.46–2.93)
1
Anaerococcus Peptoniphilus
3 Lactobacillus
Age, years
#20 1.00 1.00 1.00
21–30 0.88 (0.65–1.20) 0.93 (0.68–1.27) 1.07 (0.79–1.44)
$31 0.76 (0.51–1.11) 0.68 (0.46–1.01) 0.99 (0.70–1.42)
Sex partners, last 3 months
None 1.00 1.00 1.00
One 1.06 (0.70–1.62) 0.80 (0.52–1.21) 0.58 (0.37–0.90)
2
Two or more 1.01 (0.65–1.58) 1.13 (0.73–1.75) 0.54 (0.34–0.87)
2
HIV
Negative 1.00 1.00 1.00
Positive 1.13 (0.78–1.63) 1.88 (1.34–2.65)
1 0.66 (0.47–0.92)
2
1#0.001.
2#0.05.
3other than lacrimalis.
Results presented are the adjusted odds ratios with their 95% confidence intervals. More detailed data are available in Tables S3, S4, S5, and S6.
doi:10.1371/journal.pone.0025082.t002
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Bacterial vaginosis (%) No bacterial vaginosis (%) Odds ratio
(Nugent score$7) (Nugent score,7) (95% CI)
Age, years
#20 206 (52) 194 (48) 1.00
21–30 354 (45) 427 (55) 0.79 (0.62–1.00)
$31 149 (41) 212 (59) 0.68 (0.51–0.90)
2
Sex worker
No 446 (46) 523 (54) 1.00
Yes 263 (46) 310 (54) 0.99 (0.81–1.22)
Sex partners, last 3 months
None 68 (38) 112 (62) 1.00
One 428 (48) 456 (52) 1.58 (1.14–2.20)
2
Two or more 212 (45) 260 (55) 1.36 (0.96–1.93)
HIV
Negative 546 (44) 690 (56) 1.00
Positive 119 (55) 97 (45) 1.56 (1.17–2.07)
2
Bifidobacterium
Negative 120 (21) 454 (79) 1.00
Positive 595 (61) 379 (39) 5.94 (4.68–7.54)
1
Leptotrichia
Negative 302 (31) 673 (69) 1.00
Positive 411 (72) 161 (28) 5.69 (4.53–7.14)
1
Dialister
Negative 423 (36) 738 (64) 1.00
Positive 292 (75) 95 (25) 5.36 (4.13–6.96)
1
Eggerthella
Negative 397 (36) 718 (64) 1.00
Positive 318 (73) 116 (27) 4.96 (3.88–6.34)
1
Megasphaera elsdenii
Negative 537 (41) 781 (59) 1.00
Positive 178 (77) 53 (23) 4.88 (3.53–6.77)
1
Mycoplasma hominis
Negative 456 (38) 748 (62) 1.00
Positive 259 (74) 92 (26) 4.62 (3.54–6.02)
1
Mobiluncus
Negative 648 (44) 820 (56) 1.00
Positive 66 (78) 19 (22) 4.40 (2.61–7.40)
1
Gardenerella vaginalis
Negative 195 (27) 517 (73) 1.00
Positive 520 (62) 323 (38) 4.27 (3.44–5.29)
1
Atopobium vaginae
Negative 309 (33) 626 (67) 1.00
Positive 406 (65) 214 (35) 3.84 (3.10–4.76)
1
Prevotella
Negative 258 (31) 573 (69) 1.00
Positive 456 (63) 266 (37) 3.81 (3.08–4.70)
1
Anaerococcus
Negative 494 (40) 744 (60) 1.00
Positive 220 (71) 89 (29) 3.72 (2.84–4.88)
1
Peptoniphilus other than lacrimalis
Negative 544 (44) 695 (56) 1.00
Vaginal Flora and Bacterial Vaginosis
PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e25082flora seems plausible and may support a recent description of BV
as a ‘‘sexually enhanced disease’’ [28]. For most organisms,
prevalence decreased with age, perhaps through a decrease in
sexual activity or the progressive development of mucosal
immunity, which may wane with HIV infection. The relative
protection against BV conferred by age and the higher risk with
sexual activity and HIV infection are consistent with findings for
some of the organisms individually. In multivariate analysis, HIV
and younger age were no longer risk factors for BV, because they
were associated with colonization/infection with several bacterial
genera or species whose inclusion in the model removed the effect
of HIV and age, which lay further away in the causal pathway.
Metronidazole is an imperfect treatment of BV: 10–20% of
patients do not respond, 15–30% relapse within 3 months and half
relapse within one year [1,29]. Whether relapses may be due to
re-infections accompanying intercourse remains controversial
[29,30]. Systematically administered metronidazole has little or
no activity against M. hominis, Bifidobacterium, and G. vaginalis and
only moderate activity against Dialister [31,32]. Metronidazole has
predictable activity against Prevotella, Leptotrichia, and Eggerthella
[33,34]. Despite this resistance, metronidazole treatment does
reduce vaginal counts of M. hominis, G. vaginalis, Prevotella,
Megasphaera, and to a lower extent Leptotrichia, with little difference
between oral or intravaginal administration [32,35–37]. Topical
clindamycin, the other recommended treatment for BV [38], is not
ideal either as one-sixth of vaginal anaerobes at baseline are
resistant, and clindamycin resistance can emerge during treat-
ment, especially in Prevotella [32,39]. Nevertheless, clindamycin
appears equivalent to metronidazole in achieving a clinical cure
[40].
Counter-intuitively, we showed that after a regimen that
included either metronidazole or tinidazole, the proportion of
patients with a complete resolution of symptoms by day 14
increased with the number of pathogens present on day 0 and that
the presence of Prevotella was strongly associated with a good short-
term response. These findings may reflect the symbiotic nature of
BV such that the reduction of the metronidazole-susceptible
portion of BV pathogens results in a lack of sustainability of the
more resistant organisms and a net overall effect of clinical cure. In
the presence of multiple pathogens, the G. vaginalis-related biofilm
may be less important in the pathogenesis of BV [41].
Our study had limitations. First, we had to be selective in the
choice of pathogens to be tested on all samples, for financial and
logistical reasons. Additional BV correlates (for instance, the BV-
associated bacteria in the Clostridiales order, other Megasphaera
species, Papillibacter,o rLachnospiraceae) may have been identified
had we not faced this restriction [20,42,43]. Second, the
recruitment was performed in West Africa; whether the vaginal
flora varies between geographic regions is unknown but it does
seem to vary according to ethnicity, and genetically determined
factors could be involved in the pathogenesis of BV, as suggested
by studies in the United States where the disease is more prevalent
among African-American women, even after adjustment for sexual
behavior and other confounders [44,45]. Third, all participants,
including those that became the control group, had consulted for
vaginal discharge. One third of participants without BV had yeast
visible on Gram stain, but there is so far little evidence that the
bacterial flora of women with vaginal candidiasis is altered as
compared to that of healthy women [46]. Fourth, using extremely
sensitive molecular methods, we looked for pathogens whose
Bacterial vaginosis (%) No bacterial vaginosis (%) Odds ratio
(Nugent score$7) (Nugent score,7) (95% CI)
Positive 170 (55) 138 (45) 1.58 (1.22–2.02)
1
Lactobacillus
Negative 239 (66) 122 (34) 1.00
Positive 476 (40) 718 (60) 0.34 (0.26–0.43)
1
Trichomonas vaginals
Negative 622 (44) 778 (56) 1.00
Positive 93 (60) 62 (40) 1.94 (1.39–2.72)
1
Neisseria gonorrhoeae
Negative 676 (45) 810 (55) 1.00
Positive 39 (57) 30 (42) 1.52 (0.94–2.48)
Chlamydia trachomatis
Negative 678 (45) 817 (55) 1.00
Positive 37 (62) 23 (38) 2.00 (1.19–3.39)
2
Mycoplasma genitalium
Negative 667 (45) 811 (55) 1.00
Positive 48 (62) 29 (38) 2.06 (1.29–3.28)
2
Yeasts
Negative 507 (47) 576 (53) 1.00
Positive 208 (44) 264 (56) 0.89 (0.71–1.10)
1#0.001.
2#0.05.
doi:10.1371/journal.pone.0025082.t003
Table 3. Cont.
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definition of the outcome through the Nugent score. This problem
was potentially worse for Lactobacillus, whose morphotype (large
Gram-positive rods) accounts for 4/10 points. However, inclusion
or exclusion of Lactobacillus positivity by PCR had no effect on the
association of other pathogens with BV. Furthermore, Mobiluncus,
a curved Gram-variable rod whose morphotype corresponds to
two points, was not associated independently with the outcome.
Presumably, the overlap in the Gram stain morphology between
the various constituents of the vaginal flora and the large number
of organisms that we tested by PCR enabled us to avoid this
circular reasoning.
In conclusion, among West African women with BV, numerous
bacterial micro-organisms were strongly associated with each
other in a pattern that suggested a symbiotic relationship. Overall,
the vaginal flora of West African women with BV was reminiscent
of that of their counterparts in industrialized countries. Cases
of BV with a simpler flora were less likely to respond to
metronidazole or tinidazole. A better understanding of the
determinants of therapeutic response is needed before more
effective treatments can be developed.
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Table 4. Correlates of bacterial vaginosis (Nugent score $7)
in multivariate analysis.
Adjusted odds ratio (95% CI)
Sex partners, last 3 months
None 1.00
One 1.39 (0.92–2.08)
Two or more 0.85 (0.55–1.31)
Gardenerella vaginalis
Negative 1.00
Positive 2.35 (1.74–3.16)
1
Bifidobacterium
Negative 1.00
Positive 2.22 (1.64–3.01)
1
Megasphaera elsdenii
Negative 1.00
Positive 2.09 (1.41–3.10)
1
Dialister
Negative 1.00
Positive 1.99 (1.39–2.83)
1
Mycoplasma hominis
Negative 1.00
Positive 1.91 (1.39–2.64)
1
Leptotrichia
Negative 1.00
Positive 1.72 (1.26–2.36)
1
Prevotella
Negative 1.00
Positive 1.53 (1.15–2.03)
2
Peptoniphilus other than lacrimalis
Negative 1.00
Positive 0.56 (0.40–0.79)
1
Lactobacillus
Negative 1.00
Positive 0.26 (0.19–0.35)
1
1#0.001.
2#0.05.
doi:10.1371/journal.pone.0025082.t004
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